Skip to main content
    C

    Cartesian Therapeutics Inc. (RNAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.08
    -0.27 (-4.25%)

    Market Cap: $193.69M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cartesian Therapeutics Inc. (RNAC) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Cartesian Therapeutics (RNAC) to earn -$1.23 per share in the fiscal year ending Dec 31, 2026, on revenue of $419140. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.27.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy114.3%
    Buy685.7%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    7

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 31.8%.

    Fiscal year ending Dec 31, 2026
    -$1.23
    EPS consensus, revenue $419140
    Fiscal year ending Dec 31, 2027
    -$1.27
    EPS consensus, revenue $285710
    Next report
    Mar 8, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.23-$1.23 to -$1.231$419140$78000 to $1.00M7
    Dec 31, 2027-$1.27-$1.27 to -$1.271$285710N/A7

    Quarterly Estimates

    The EPS consensus rises from -$0.95 for the quarter ending Dec 31, 2026 to -$0.86 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.95-$1.18 to -$0.419$348503N/A9
    Mar 31, 2027-$0.86-$1.09 to -$0.426$41670N/A6

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202721

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.78.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.23-$2.78-$2.78-$2.78-$2.78N/A
    Fiscal year ending Dec 31, 2027-$1.27-$3.81-$3.81-$3.81-$3.81N/A
    Quarter ending Mar 31, 2027-$0.86-$1.05-$1.05-$1.05-$1.05N/A

    Frequently Asked Questions About RNAC

    What is the RNAC stock forecast?

    Consensus analyst estimates put Cartesian Therapeutics's EPS at -$1.23 for the fiscal year ending Dec 31, 2026, on revenue of $419140. The consensus rating from 7 analysts is Buy.

    How do analysts rate RNAC stock?

    Of 7 analysts covering Cartesian Therapeutics, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from RNAC next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.23, with estimates from -$1.23 to -$1.23 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.27, with estimates from -$1.27 to -$1.27 from 1 analyst.

    What revenue do analysts expect from Cartesian Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $419140, with estimates from $78000 to $1.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $285710.

    How many analysts cover RNAC?

    7 analysts rate Cartesian Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.